InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,471.05
(
1.16%
)
US TECH 100
18,204.80
(
1.43%
)
Dow Jones
40,829.59
(
1.20%
)
Brent Oil
71.60
(
-0.17%
)
Bitcoin
56,567.35
(
-0.80%
)
Post# of 438
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DanWebzster

Send PM Follow Ignore
Followers 10
Posts 1060
Boards Moderated 2
Alias Born 09/04/2000

DanWebzster

Member Level

Re: DanWebzster post# 40

Friday, 03/09/2018 11:33:52 AM

Friday, March 09, 2018 11:33:52 AM

Post# of 438
AVDL

difficulty enrolling patients for its Ph3 narcolepsy study pushes this story out to 2019

When/if their sodium oxybate treatment successfully reads out, AVDL would be poised to take some of JAZZ 1Bn xyrem blockbuster revenues.

Their recently in-licensed and previously approved nocturia drug is their near-term focus. They must complete another ph3 study and prepare for its commercial launch

The nocturia treatment will likely be launched 2Q2018. I'm doubtful that it will contribute significantly to the bottom line
in 2018.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up